Marien Hospital Düsseldorf

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Myeloproliferative neoplasms2 trials
• Acute lymphoblastic leukaemia1 trial
• Acute myeloid leukaemia1 trial
• Chronic lymphocytic leukaemia1 trial
• Immune thrombocytopenia (ITP)1 trial
• Lung cancer1 trial
• Mantle cell lymphoma1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 35 trials
• Phase 22 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Recruiting5 trials
• Active, not recruiting2 trials
• Completed2 trials
• Withdrawn1 trial

Lead sponsor

• Karyopharm Therapeutics Inc2 trials
• Celgene1 trial
• Eli Lilly and Company1 trial
• GCP-Service International West GmbH1 trial
• German CLL Study Group1 trial
• and 4 more

Running trials

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Pfizer· Source

• Recruiting

  A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  NCT05980806· Phase 2· Karyopharm Therapeutics Inc· Source

  Contact: Stefanie Groepper (principal investigator)

• Recruiting

  A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  NCT05519085· Phase 3· Celgene· Source

  Contact: Maika Klaiber-Hakimi, Site 0415

• Recruiting

  A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

  NCT05197192· Phase 3· German CLL Study Group· Source

  Contact: Stefanie Gröpper

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Karyopharm Therapeutics Inc· Source

• Active, not recruiting

  A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

  NCT02246621· Phase 3· Eli Lilly and Company· Source

• Recruiting

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Goethe University· Source

  Contact: Nicola Gökbuget, Dr. med.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting

Closed trials

• Withdrawn

  The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

  NCT06291415· Phase 1· Hutchmed· Source

• Completed

  Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  NCT05583552· Phase 2· GCP-Service International West GmbH· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· The Lymphoma Academic Research Organisation· Source